Greenbriar invites investors both retail & institutional, as well as finance professionals, advisors and analysts, to participate in a real-time, interactive presentation. Greenbriar Capital Corp (TSXV: GRB) (OTC: GEBRF) (“Greenbriar”), is pleased to announce that Jeff Ciachurski, CEO & Director, will present live at Grit Capital’s #ESG Investor Webcast Live on March 25th, 2020 at 1:00pm ET/10:00am PT. DATE: March 25th, 2020 TIME: 1:00pm ET/10:00am PT FORMAT: Live 10 minutes presentation & 5 minutes Q&A session LINK: https://event.on24.com/wcc/r/2219187/A56D3D8FEA459BB0F66306AFABE17792 This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not…
Author: Marie Jones
Read More
TOKYO, Mar 23, 2020 – (JCN Newswire) – HC Holdings K.K., a wholly-owned subsidiary of Showa Denko K.K. (“Showa Denko”; TSE: 4004), (the “Tender Offeror”, collectively with Showa Denko, the “Tender Offerors”), as announced by the Tender Offerors in the “Announcement Regarding the Planned Commencement of Tender Offer for Shares in Hitachi Chemical Company, Ltd. (TSE: 4217)” as of December 18, 2019, decided on the same day, through the Tender Offeror’s representative officer, to acquire common shares (the “Target Shares”) of Hitachi Chemical Company, Ltd. (the “Target Company” listed on the First Section of Tokyo Stock Exchange, Inc. (the “Tokyo Stock Exchange”) under the…
Starting from a meteoric rise to fame in San Francisco as an iconic fashion and street photographer, Christopher C. Lee has riveted the attention of photography lovers nationwide with the grand opening of his boutique photography studio, Christopher C. Lee Photography & Film. He is also renowned as a portrait photographer who is able to “bring out the soul” of his subjects, capturing them in timeless frames. Chris is the founder of Photomochi (https://www.photomochi.com), an acclaimed Bay Area production studio, the lead designer of streetwear label Troo Wear (https://www.troowear.com), and the top-selling author of “The Japan Book”, a cult classic…
Starting from a meteoric rise to fame in San Francisco as an iconic fashion and street photographer, Christopher C. Lee has riveted the attention of photography lovers nationwide with the grand opening of his boutique photography studio, Christopher C. Lee Photography & Film. He is also renowned as a portrait photographer who is able to “bring out the soul” of his subjects, capturing them in timeless frames. Chris is the founder of Photomochi (https://www.photomochi.com), an acclaimed Bay Area production studio, the lead designer of streetwear label Troo Wear (https://www.troowear.com), and the top-selling author of “The Japan Book”, a cult classic…
Realization of Financial Innovation; Attaining Remarkable Achievements in Operating income Bank of Tianjin Co., Ltd. (“Bank of Tianjin” or the “Bank”; Stock Code: 1578.HK) hereby announces the audited consolidated annual results of the Company for the twelve months ended December 31, 2019 (the “Reporting Period”). Financial Summary – The bank materialized an operating income of RMB17.053 billion in 2019, representing an increase of 40.5% as compared to 2018, achieving a record high; – The Bank materialized net interest income of RMB14.65 billion (including “investment income”), representing an increase of 39.6% as compared to 2018; – Profit before provision of RMB13.06…
The four core segments grew steadily. Improvement of profitability led to a substantial increase in net profit attributable to equity shareholders Tiangong International Company Limited (“Tiangong International” or the “Group”; Stock Code: 0826.HK), the world’s leading manufacturer of high-end new materials, was pleased to announce its consolidated annual results for the year ended 31 December 2019 today. Financial Highlights – Revenue increased 6.9% to RMB5,370 million – Gross profit increased 17.9% to RMB1,020 million – Net profit attributable to equity shareholders increased 52.7% to RMB395 million 2019 is a year of growth for the Group. Total revenue increased by 6.9%…
InnoCare Pharma Limited (“InnoCare” or the “Company”) (09969.HK), as the first listed biotech company in 2020, is listed on the Main Board of the Stock Exchange of Hong Kong (HKEX) today. Investors swarmed to subscribe to the shares during the offering period. The public offering in Hong Kong was oversubscribed by nearly 300 times. The final price per share of InnoCare was HKD8.95. Approximately HKD2.24 billion was raised. Morgan Stanley Asia Limited and Goldman Sachs (Asia) L.L.C. are the Joint Sponsors. Since its incorporation in November 2015, the Company has identified and developed nine drug candidates, and conducted clinical trials…
TOKYO – (JCN Newswire) – Consultants at Azabu Insights wanted to understand the stark differences between mortality rates in Korea (currently 1.1%) and Italy (8.3%). We felt that current explanations suggested by virologists, while making a number of valid points, have ultimately been unsatisfactory. Azabu Insights presents the hypothesis that hospitals may have been one of the breeding grounds for virus infection in Italy and this may have been one of the causes of the high mortality rates. This is a major concern, going forward, for other countries including the United States. Azabu Insights recommends that policy experts and hospital…
SYDNEY – (ACN Newswire) – Asia-Pacific’s largest specialist biotech CRO Novotech has been selected as a finalist in two categories for the Citeline Awards 2020 (formerly CARE Awards), hosted by Informa Pharma Intelligence, scheduled this year on September 17th. The categories are Clinical Research Team of the Year, and Medidata Clinical Partnership of the Year. Dr John Moller, Novotech CEO, said, “These are major milestones for the company, and further recognition of Novotech as the premier CRO in Asia-Pacific. We are particularly thrilled that the Medidata Clinical Partnership of the Year recognizes Novotech and its Chinese partner PPC, for excellence…
Silicon Valley entrepreneur and Nobel Laureate Protege Dr. Ned Saleh announced today that the compact blood-testing device invented by his startup Synsal Inc. could have detected the Coronavirus outbreak and saved lives had it been deployed in the mass market. Saleh stated Synsal’s technology has been verified on a similar infectious pathogen using a method called Reverse-Transcription Loop-mediated isothermal AMPlifications or RT-LAMP. The new programmable technology — comparable in cost to a cell phone — is an innovative compact device that detects a wide range of wellness panels and human relevant biomarkers from a few drops of blood or bodily…
TRACEsafe offers a socially vital monitoring technology product that can be deployed to governments around the world to help protect citizens and slow the spread of COVID-19. Blockchain Holdings Ltd. (“Blockchain”) (CSE:BCX), a public company listed on the Canadian Securities Exchange under the symbol “BCX”, today announced that effective March 13, 2020, it entered into a binding letter of intent (the “Transaction”) to acquire 100% of the rights and interests in a self-quarantine monitoring technology suite known collectively as “IMSafe” from WiSilica, Inc. (“WiSilica”). TRACEsafe is a global health monitoring product that may be deployed by governments and corporations as…
Both Revenue And Net Profit Harvest, The Profit Attributable To Shareholders Increased By 48.5% Sichuan Languang Justbon Services Group CO., LTD. (the “Company” or “Languang Justbon”, Stock Code: 2606.HK) today is pleased to announce the audited consolidated results of the Company and its subsidiaries (collectively, the “Group”) for the year ended 31 December 2019 (“Reporting Period”). Financial summary: – The revenue increased to RMB2,100.2 million, representing an increase of approximately 43.4%, the gross profit increased to RMB760.2 million, representing an increase of approximately 56.2%, the gross profit margin increased to 36.2% ; – The Net profit increased to RMB444.1 million,…
The Universal Protocol Alliance, a coalition of leading blockchain organizations including Bittrex Global, Cred (mycred.io), Uphold (uphold.com), Blockchain at Berkeley, and CertiK (certik.org), today announced the listing of three tokens on Bittrex Global: the Universal Dollar (UPUSD), the Universal Euro (UPEUR), and the Universal Protocol Token (UPT). The Universal Dollar (UPUSD) is a USD-pegged stablecoin collateralized 1:1 with the US Dollar, the Universal Euro (UPEUR) is a EURO-pegged stablecoin collateralized 1:1 with the EURO, and the Universal Protocol Token (UPT) is the Alliance utility token that will offer holders valuable benefits from Alliance members. Bittrex Global will be offering a…
The “True Art of Investments is Boundless”: Confident of Record Performance in 2020 As the markets contemplate the ‘darkest week since the global financial crisis in 2008’, experts have warned that it could take months, or perhaps a year or two for a full-scale crisis to resolve. For most of the world, this would spell disaster, especially central banks and monetary authorities; yet for some, the uncertainty represents a spectrum of opportunities for investments. As a Chinese investment firm, Fa Xian Xian Ji (Beijing) Investments Co., Ltd. describes it somewhat philosophically, “The true art of investments is boundless.” In a…
澳大利亞CRO Avance Clinical今天表示，澳大利亞快速的監管審批環境，關鍵意見領袖的專業知識和高質量的臨床研究中心，以及頗具吸引力的40%的政府臨床試驗支出退稅，所有這一切都意味著Avance具有得天獨厚的優勢，能夠使緊迫的COVID-19試驗速見成效。 澳大利亞CRO Avance Clinical今天表示，澳大利亞快速的監管審批環境，關鍵意見領袖的專業知識和高質量的臨床研究中心，以及頗具吸引力的40%的政府臨床試驗支出退稅，所有這一切都意味著Avance具有得天獨厚的優勢，能夠使緊迫的COVID-19試驗速見成效。 Avance Clinical在CRO領域擁有20年的經驗，並在過去5年中一直在進行疫苗和傳染病試驗。 Avance顯然是針對COVID-19試驗的首選CRO。 Avance Clinical首席執行官Yvonne Lungershausen表示：“重要的是，澳大利亞政府提供了超過40％的研發現金退稅，再加上當前匯率頗具吸引力。這使得澳大利亞成為進行臨床試驗最划算的地區之一。” 澳大利亞一向以卓越的科研實力，先進的醫療保健水平以及在臨床試驗競爭較少的環境中擁有更多招募病人的機會而著稱，這進一步鞏固了其作為當前COVID-19試驗地點的優勢。 Avance的首席戰略官Ben Edwards表示：“我們公司在該領域的專業技術和知識深度使我們成為任何尋求研發COVID-19療法的生物技術公司的首選CRO。” “另外值得特別強調的一點是，根據目前的趨勢，澳大利亞可能是受COVID-19影響最小的國家之一。” 我們預計，在整個世界適應COVID-19疫情的這段時間內，這一點可以使其對臨床試驗活動的干擾降到最低。 ” Lungershausen女士表示，總體而言，我們預計公司目前管理的所有治療適應症項目的進展和時間表都不會受到重大干擾。她說：“我們團隊與遠程客戶和臨床服務提供商合作的經驗以及我們的虛擬通信系統和流程使我們在保持當前項目發展勢頭方面處於明顯優勢。” “我們的團隊對項目的遠程通信和管理已經是駕輕就熟了，” Edwards先生說。 澳大利亞的臨床研究機構已經對COVID-19流行病所帶來的挑戰做出了響應，實施了多項旨在保護患者和公眾利益的措施和製度，同時還力求最大程度地減少對臨床研究活動的干擾。 Avance臨床運營團隊與試驗地點不間斷地溝通，接收有關程序不斷更新變化的最新信息，並有效管理與Avance所轄項目有關的活動。 “Avance Clinical擁有一系列可用的工具對中心和客戶提供支援，在這一頗具挑戰性的時期成功完成他們的試驗。這些都將被仔細管理，以確保研究的合規性，” Lungershausen女士說。 想了解更多關於在澳大利亞開展您下一項研究的優勢，請聯繫我們： https://www.avancecro.com/contact-us/ 關於 Avance Clinical Avance Clinical擁有20多年的從業經驗，目前是澳大利亞領先的合同研究機構之一。 Avance Clinical通過協調人員、技能和專業知識，促進高質量的藥物開發，以追求更健康的世界。 AvanceClinical憑藉其經驗豐富的團隊，致力於提供高質量的臨床研究服務。 Avance Clinical的知識和經驗庫也得益於精心挑選的專家在不斷地擴張，這些專家也表現出對所選領域的高度熱情。 Avance Clinical在成熟的臨床試驗生態系統中提供高質量的服務，包括世界級的研究人員和能夠訪問特定患者組群的中心。其他好處還包括： – 在澳大利亞各地使用獨立的一期設施，包括醫院內部設立的重症護理中心 – 致力於臨床研究的專業研究人員 – 擁有世界級基礎設施和專門臨床試驗中心的大型醫院 – 縮短臨床試驗的啟動時間 媒體聯絡: Media@AvanceCRO.com Chris Thompson
澳大利亚CRO Avance Clinical今天表示，澳大利亚快速的监管审批环境，关键意见领袖的专业知识和高质量的临床研究中心，以及颇具吸引力的40%的政府临床试验支出退税，所有这一切都意味着Avance具有得天独厚的优势，能够使紧迫的COVID-19试验速见成效。 Avance Clinical在CRO领域拥有20年的经验，并在过去5年中一直在进行疫苗和传染病试验。Avance显然是针对COVID-19试验的首选CRO。 Avance Clinical首席执行官Yvonne Lungershausen表示：“重要的是，澳大利亚政府提供了超过40％的研发现金退税，再加上当前汇率颇具吸引力。这使得澳大利亚成为进行临床试验最划算的地区之一。” 澳大利亚一向以卓越的科研实力，先进的医疗保健水平以及在临床试验竞争较少的环境中拥有更多招募病人的机会而著称，这进一步巩固了其作为当前COVID-19试验地点的优势。 Avance的首席战略官Ben Edwards表示：“我们公司在该领域的专业技术和知识深度使我们成为任何寻求研发COVID-19疗法的生物技术公司的首选CRO。” “另外值得特别强调的一点是，根据目前的趋势，澳大利亚可能是受COVID-19影响最小的国家之一。” 我们预计，在整个世界适应COVID-19疫情的这段时间内，这一点可以使其对临床试验活动的干扰降到最低。” Lungershausen女士表示，总体而言，我们预计公司目前管理的所有治疗适应症项目的进展和时间表都不会受到重大干扰。她说：“我们团队与远程客户和临床服务提供商合作的经验以及我们的虚拟通信系统和流程使我们在保持当前项目发展势头方面处于明显优势。” “我们的团队对项目的远程通信和管理已经是驾轻就熟了，” Edwards先生说。 澳大利亚的临床研究机构已经对COVID-19流行病所带来的挑战做出了响应，实施了多项旨在保护患者和公众利益的措施和制度，同时还力求最大程度地减少对临床研究活动的干扰。 Avance临床运营团队与试验地点不间断地沟通，接收有关程序不断更新变化的最新信息，并有效管理与Avance所辖项目有关的活动。 “Avance Clinical拥有一系列可用的工具对中心和客户提供支援，在这一颇具挑战性的时期成功完成他们的试验。这些都将被仔细管理，以确保研究的合规性，” Lungershausen女士说。 想了解更多关于在澳大利亚开展您下一项研究的优势，请联系我们： https://www.avancecro.com/contact-us/ 关于 Avance Clinical Avance Clinical拥有20多年的从业经验，目前是澳大利亚领先的合同研究机构之一。 Avance Clinical通过协调人员、技能和专业知识，促进高质量的药物开发，以追求更健康的世界。 AvanceClinical凭借其经验丰富的团队，致力于提供高质量的临床研究服务。Avance Clinical的知识和经验库也得益于精心挑选的专家在不断地扩张，这些专家也表现出对所选领域的高度热情。 Avance Clinical在成熟的临床试验生态系统中提供高质量的服务，包括世界级的研究人员和能够访问特定患者组群的中心。其他好处还包括： – 在澳大利亚各地使用独立的一期设施，包括医院内部设立的重症护理中心 – 致力于临床研究的专业研究人员 – 拥有世界级基础设施和专门临床试验中心的大型医院 – 缩短临床试验的启动时间 媒体联络: Media@AvanceCRO.com Chris Thompson
Smartac Group China Holdings Limited (HKEX: 395) (“Smartac” or the “Group”) has announced that the Group has entered into franchise agreements with STELLA MCCARTNEY LIMITED (“SMC”), STELLA MCCARTNEY ITALIA SRL and STELLA MCCARTNEY KIDS ITALIA SRL. The agreements grant the Group the right to sell (i) SMC’s mainline of ready to wear products comprising fashion apparel and accessories; and (ii) SMC’s mainline of kids products comprising kids fashion apparel and accessories. Both lines are to be sold to consumers in Mainland China on the designated online sales platforms operated by the Group for three years effective from 1 January 2020…
The award-winning global leader in digital patient recruitment, GeoMap Clinical said it was seeing more demand for clinical trial patient recruitment in China and South Korea as the two regions reported a drop in COVID-19 infections. GeoMap is working closely with biotechs and CROs around the world to keep screening patients and connecting them with study coordinators online to support important ongoing clinical research amid the COVID-19 crisis. The Platform recruits for clinical trials in North America, Latin America, Australia, New Zealand, China, South Korea, Singapore, Thailand, and the EU. The company said, “GeoMap has seen a surge in demand…
Adelaide, AUS, Mar 20, 2020 – (ACN Newswire) – Australian CRO Avance Clinical said today that Australia’s fast regulatory approval environment, key opinion leader expertise and high-quality clinical research sites, as well as the attractive 40% Government rebate on clinical trial spend, means Avance is uniquely positioned to deliver rapid results for urgent COVID-19 trials. Avance Clinical offers 20-years of experience in the CRO sector, and has conducted vaccine and infectious diseases trials in the past 5 years. Avance is clearly the CRO of choice for trials targeting COVID-19. “Importantly, the more than 40% R&D cash rebate from the Australian…
Net Profit Up 39.3% to RMB295.1 Million; Income from Factoring and Other Services Surges 29.0% to RMB606.7 Million Sheng Ye Capital Limited (“Sheng Ye Capital” or the “Group”; Stock code: 6069), a data-driven supply chain financial services provider offering accounts receivable financing and other related solutions mainly in the energy, construction and medical sectors in China, has today announced its first audited consolidated annual results for the year ended 31 December 2019 (“FY2019”) since transferring its listing from GEM to the Main Board of The Stock Exchange of Hong Kong Limited (“HKEX”) on 24 October 2019. The Group recorded pleasing…